Jazz Pharmaceuticals (JAZZN) AI Stock Analysis
Jazz Pharmaceuticals
(BMV:JAZZN)
No summary available
Jazz Pharmaceuticals (JAZZN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 14.02B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 14.2
- Beta (1Y)
- -0.48
- Revenue Growth
- 2.62%
- EPS Growth
- ―
- Country
- Mexico
- Employees
- 2,890
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Jazz Pharmaceuticals Business Overview & Revenue Model
Company Description
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...
Jazz Pharmaceuticals Earnings Call Summary
The call presented multiple strong commercial and pipeline wins — record revenue, raised guidance, double-digit growth across key brands (oncology +32%, Xywav +13%, Epidiolex +16%, Zepzelca +42%) and a solid balance sheet — while acknowledging manageable margin pressure from royalties, rising SG&A/R&D investments, label adjustments for Zepzelca second-line, and potential future competitive/generic risks for the oxybate franchise. On balance, the positive execution, guidance raise, cash generation and late-stage regulatory momentum outweigh the identified challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised 2026 revenue guidance to $4.60–$4.75 billion and set rare-sleep revenue at $2.025–$2.125 billion, citing record Q2 revenue of $1.21 billion (16% YoY), strong oncology growth (+32% Y/Y), and robust first‑half operating cash flow of $824 million and $2.2 billion cash on the balance sheet; they expect double‑digit Xywav growth in 2026, modestly higher SG&A guidance (non‑GAAP SG&A and R&D each rose 11% this quarter), a slightly lower non‑GAAP gross margin, a non‑GAAP effective tax rate moderately above prior guidance, updated fully diluted share count guidance to 69–70 million shares, and reported Q2 non‑GAAP EPS of $5.71 (including $0.94 of IPR&D charges), with product-level drivers including Xywav Q2 sales of $471 million (~525 net patient adds; ~17,125 active patients, >12% YoY), Epidiolex $292 million (16% Y/Y; ~12% volume growth), Zepzelca $106 million (42% Y/Y), Modeyso $48 million and Ziihera $15 million.
Jazz Pharmaceuticals Risk Analysis
Jazz Pharmaceuticals disclosed 47 risk factors in its most recent earnings report. Jazz Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksJazz Pharmaceuticals Peers Comparison
Overall Rating
NBIX84Outperform
HRMY76Outperform
XENE60Neutral
PRAX52Neutral
AXSM47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NBIX | 84Outperform | $14.85B | 20.72 | 21.13% | ― | 34.42% | 102.44% |
| HRMY | 76Outperform | $2.26B | 12.38 | 20.06% | ― | 24.25% | -0.83% |
| XENE | 60Neutral | $3.62B | -7.89 | -43.98% | ― | -100.00% | -33.88% |
| PRAX | 52Neutral | $7.98B | -22.08 | -34.15% | ― | -100.00% | -5.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AXSM | 47Neutral | $7.57B | -38.51 | -255.60% | ― | 56.87% | 25.87% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:JAZZN | Jazz Pharmaceuticals | 2985.00 | 850.00 | 39.81% | |
| NBIX | Neurocrine Biosciences | 146.10 | 4.14 | 2.92% | |
| XENE | Xenon Pharmaceuticals | 37.41 | -3.71 | -9.02% | |
| AXSM | Axsome Therapeutics Inc. | 144.43 | 8.68 | 6.39% | |
| HRMY | Harmony Biosciences Holdings, Inc. | 38.76 | 9.43 | 32.15% | |
| PRAX | Praxis Precision Medicines, Inc. | 285.93 | 103.94 | 57.11% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.